DBV Technologies Receives IND Clearance From FDA To Begin Clinical Trial In Peanut Allergy
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application.